Hydroxypioglitazone; 146062-44-4; Leriglitazone; Hydroxy Pioglitazone (M-IV); MIN-102; CHEBI:82937; Leriglitazone [USAN]; 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; K824X25AYA; 2,4-Thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-; 2,4-Thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-; Hydroxy Pioglitazone-d4 (M-IV) (deuterated); Hydroxy Pioglitazone; 1-Hydroxypioglitazone; Pioglitazone, hydroxy; LERIGLITAZONE [INN]; Leriglitazone (USAN/INN); CHEMBL1267; UNII-K824X25AYA; SCHEMBL4098326; DTXSID30399914; BDBM50530214; WHO 10868; ZINC01482947; AKOS015856344; DB15021; 5-[[4-[2-[5-(1-Hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione; Hydroxy Pioglitazone (M-IV Metabolite); DB-042820; HY-117727; CS-0067030; FT-0643388; D11603; U-91322; A1-01710; J-008187; Q27156475; 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione; 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione; ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE